{"protocolSection":{"identificationModule":{"nctId":"NCT00700180","orgStudyIdInfo":{"id":"BO21015"},"secondaryIdInfos":[{"id":"2008-000662-23"}],"organization":{"fullName":"Hoffmann-La Roche","class":"INDUSTRY"},"briefTitle":"A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.","officialTitle":"A Randomized, Open-label Study to Explore the Correlation of Biomarkers With Response Rate in Chemo-naive Patients With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer Who Receive Treatment With Avastin in Addition to Carboplatin-based Chemotherapy"},"statusModule":{"statusVerifiedDate":"2014-09","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2008-09"},"primaryCompletionDateStruct":{"date":"2012-09","type":"ACTUAL"},"completionDateStruct":{"date":"2012-09","type":"ACTUAL"},"studyFirstSubmitDate":"2008-06-17","studyFirstSubmitQcDate":"2008-06-17","studyFirstPostDateStruct":{"date":"2008-06-18","type":"ESTIMATED"},"resultsFirstSubmitDate":"2014-09-16","resultsFirstSubmitQcDate":"2014-09-23","resultsFirstPostDateStruct":{"date":"2014-09-25","type":"ESTIMATED"},"lastUpdateSubmitDate":"2014-09-23","lastUpdatePostDateStruct":{"date":"2014-09-25","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Hoffmann-La Roche","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"This study will explore the correlation of biomarkers with response rate, and the overall efficacy and safety, of Avastin in combination with carboplatin-based chemotherapy in patients with advanced or recurrent non-squamous non-small cell lung cancer. Patients will be randomized to one of 2 groups, to receive either Avastin 7.5mg/kg iv on day 1 of each 3 week cycle, or Avastin 15mg/kg iv on day 1 of each 3 week cycle; all patients will also receive treatment with carboplatin and either gemcitabine or paclitaxel for a maximum of 6 cycles. The anticipated time on study treatment is until disease progression, and the target sample size is 100-500 individuals."},"conditionsModule":{"conditions":["Non-Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":303,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: bevacizumab [Avastin]","Drug: Carboplatin-based chemotherapy"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Drug: bevacizumab [Avastin]","Drug: Carboplatin-based chemotherapy"]}],"interventions":[{"type":"DRUG","name":"bevacizumab [Avastin]","description":"7.5mg/kg iv on day 1 of each 3 week cycle","armGroupLabels":["1"]},{"type":"DRUG","name":"bevacizumab [Avastin]","description":"15mg/kg iv on day 1 of each 3 week cycle","armGroupLabels":["2"]},{"type":"DRUG","name":"Carboplatin-based chemotherapy","description":"As prescribed","armGroupLabels":["1","2"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) by Dichotomized Baseline Plasma Marker Level","description":"Overall response was analyzed and correlated within dichotomized (low- and high-level) baseline plasma biomarker (basic fibroblast growth factor \\[bFGF\\], E-selection, intracellular adhesion molecule \\[ICAM\\], placental growth factor \\[PlGF\\], vascular endothelial growth factor A \\[VEGF A\\], vascular endothelial growth factor receptor \\[VEGFR\\]-1, and VEGFR-2) subgroups: low-level equals (=) less than or equal to (≤) median baseline level, high-level=greater than (\\>) median baseline level. Per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.0 CR defined as disappearance of all target lesions, non-target lesions, and normalization of tumor marker level. PR defined as greater than or equal to (≥)30 percent (%) decrease under baseline of the sum of the longest diameter (LD) of all target lesions. No unequivocal progression of non-target disease; no new lesions. Complete and partial responses must have been confirmed no less than 4 weeks after criteria for response were first met","timeFrame":"Baseline, Day 21 of Cycles 2, 4, and 6 (Bv + chemo), Day 21 of Cycles 7, 8, 9, and 10 (Bv), Day 21 of every other cycle (Bv), and at disease progression."}],"secondaryOutcomes":[{"measure":"Progression-Free Survival - Percentage of Participants With an Event","description":"PFS was defined as the time between randomization and progressive disease (PD) according to RECIST criteria, or death due to any cause. PD was defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started. Disease progression was evaluated according to the RECIST using computed tomography (CT) scans, magnetic resonance imaging (MRI) scans, X-ray, bone scans, or clinical examination. Participants without an event were censored at the date of last follow up for progression. Participants with no post baseline follow-up for progression were censored at the day of randomization.","timeFrame":"Baseline, Day 1, weekly to disease progression"},{"measure":"Progression-Free Survival - Time to Event","description":"PFS was defined as the time between randomization and disease progression or death due to any cause. Participants without an event were censored at the date of last follow up for progression. Participants with no post baseline follow-up for progression were censored at the day of randomization. Disease progression was evaluated according to the RECIST using CT scans, MRI scans, X-ray, bone scans, or clinical examination. Median PFS was estimated using the Kaplan-Meier method.","timeFrame":"Baseline, Day 1, weekly to disease progression"},{"measure":"Percentage of Participants With Objective Response","description":"Percentage of participants with CR or PR according to RECIST criteria. Per RECIST v1.0: CR defined as disappearance of all target lesions, non-target lesions, and normalization of tumor marker level. PR was defined as ≥30% decrease under baseline of the sum of the LD of all target lesions. No unequivocal progression of non-target disease. No new lesions. Complete and partial responses were confirmed no less than 4 weeks after the criteria for response were first met.","timeFrame":"Baseline, Day 21 of Cycles 2, 4, and 6, Day 21 of Cycles 7, 8, 9, and 10, Day 21 of every other cycle, and at disease progression"},{"measure":"Percentage of Participants With Measurable Disease at Baseline Who Achieved CR, PR, or Stable Disease (SD) for at Least 6 Weeks","description":"Percentage of participants with measurable disease at baseline who on assessment achieved CR, PR, or SD according to RECIST. Per RECIST v1.0: CR defined as disappearance of all target lesions, non-target lesions, and normalization of tumor marker level. PR was defined as ≥30% decrease under baseline of the sum of the LD of all target lesions. No unequivocal progression of non-target disease. No new lesions. SD defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum LD since start of treatment. Complete and partial responses must have been confirmed no less than 4 weeks after the criteria for response were first met. For participants with SD, follow-up assessments must have met the SD criteria at least once after study entry at a minimum interval of 6 weeks.","timeFrame":"Baseline, Day 21 of Cycles 2, 4, and 6, Day 21 of Cycles 7, 8, 9, and 10, Day 21 of every other cycle, and at disease progression"},{"measure":"Duration of Response - Percentage of Participants With an Event","description":"Duration of response is defined as time in months from the first documentation of objective tumor response (CR or PR) to objective tumor progression or death due to any cause. Participants without an event (documented progression or death) were censored at the date of last follow-up for progression. Duration of response was only calculated for participants who had a confirmed objective tumor response (CR or PR).","timeFrame":"Baseline, Day 21 of Cycles 2, 4, and 6, Day 21 of Cycles 7, 8, 9, and 10, Day 21 of every other cycle, and at disease progression"},{"measure":"Duration of Response - Time to Event","description":"The median time, in months, from the first documentation of objective tumor response (CR or PR) to objective tumor progression or death due to any cause. Participants without an event (documented progression or death) were censored at the date of last follow-up for progression. Duration of response was only calculated for participants who had a confirmed objective tumor response (CR or PR). Median Duration of Response was estimated using the Kaplan-Meier method.","timeFrame":"Baseline, Day 21 of Cycles 2, 4, and 6 (Bv + chemo), Day 21 of Cycles 7, 8, 9, and 10 (Bv), Day 21 of every other cycle (Bv), and at disease progression."},{"measure":"Overall Survival - Percentage of Participants With an Event","description":"Overall survival was defined as the time between randomization and death due to any cause. Participants without an event were censored at the last time they were known to be alive. Overall Survival was estimated using the Kaplan-Meier method.","timeFrame":"Baseline, weekly to 28 days after last dose of study treatment, every 8 weeks thereafter to death due to any cause"},{"measure":"Overall Survival - Time to Event","description":"Overall survival was defined as the time between randomization and death due to any cause. Participants without an event were censored at the last time they were known to be alive. Overall Survival was estimated using the Kaplan-Meier method.","timeFrame":"Baseline, weekly to death due to any cause, or to end of study"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* adult patients, \\>=18 years of age;\n* locally advanced metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC);\n* \\>=1 measurable tumor lesion;\n* ECOG performance status 0-1.\n\nExclusion Criteria:\n\n* prior chemotherapy or treatment with another systemic anti-cancer agent;\n* evidence of CNS metastases;\n* history of grade 2 or higher hemoptysis;\n* evidence of tumor invading or abutting major blood vessels;\n* malignancies other than NSCLC within 5 years prior to randomization, other than adequately treated cancer in situ of cervix, basal or squamous cell skin cancer, localized prostate cancer or DCIS;\n* clinically significant cardiovascular disease;\n* current or recent use of aspirin (\\>325mg/day) or full dose anticoagulants or thrombolytic agents for therapeutic purposes.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Clinical Trials","affiliation":"Hoffmann-La Roche","role":"STUDY_DIRECTOR"}],"locations":[{"city":"St Leonards","state":"New South Wales","zip":"2065","country":"Australia","geoPoint":{"lat":-33.82344,"lon":151.19836}},{"city":"Adelaide","state":"South Australia","zip":"5041","country":"Australia","geoPoint":{"lat":-34.92866,"lon":138.59863}},{"city":"Adelaide","state":"South Australia","zip":"5065","country":"Australia","geoPoint":{"lat":-34.92866,"lon":138.59863}},{"city":"Box Hill","state":"Victoria","zip":"3128","country":"Australia","geoPoint":{"lat":-37.81887,"lon":145.12545}},{"city":"Fitzroy","state":"Victoria","zip":"3065","country":"Australia","geoPoint":{"lat":-37.79839,"lon":144.97833}},{"city":"Antwerp","zip":"2020","country":"Belgium","geoPoint":{"lat":51.22047,"lon":4.40026}},{"city":"Liège","zip":"4000","country":"Belgium","geoPoint":{"lat":50.63373,"lon":5.56749}},{"city":"Vancouver","state":"British Columbia","zip":"V5Z 4E6","country":"Canada","geoPoint":{"lat":49.24966,"lon":-123.11934}},{"city":"Toronto","state":"Ontario","zip":"M5G2M9","country":"Canada","geoPoint":{"lat":43.70643,"lon":-79.39864}},{"city":"Ostrava","zip":"708 52","country":"Czechia","geoPoint":{"lat":49.83465,"lon":18.28204}},{"city":"Prague","zip":"180 01","country":"Czechia","geoPoint":{"lat":50.08804,"lon":14.42076}},{"city":"Odense","zip":"5000","country":"Denmark","geoPoint":{"lat":55.39594,"lon":10.38831}},{"city":"Paris","zip":"75970","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"city":"Rouen","zip":"76031","country":"France","geoPoint":{"lat":49.44313,"lon":1.09932}},{"city":"Bad Berka","zip":"99437","country":"Germany","geoPoint":{"lat":50.89982,"lon":11.28245}},{"city":"Großhansdorf","zip":"22927","country":"Germany","geoPoint":{"lat":53.66528,"lon":10.28552}},{"city":"Hamburg","zip":"21075","country":"Germany","geoPoint":{"lat":53.55073,"lon":9.99302}},{"city":"Oldenburg","zip":"26121","country":"Germany","geoPoint":{"lat":53.14118,"lon":8.21467}},{"city":"Hong Kong","zip":"852","country":"Hong Kong","geoPoint":{"lat":22.27832,"lon":114.17469}},{"city":"Hong Kong","country":"Hong Kong","geoPoint":{"lat":22.27832,"lon":114.17469}},{"city":"Budapest","zip":"1529","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"city":"Edelény","zip":"3780","country":"Hungary","geoPoint":{"lat":48.3,"lon":20.73333}},{"city":"Sopron","zip":"9400","country":"Hungary","geoPoint":{"lat":47.68501,"lon":16.59049}},{"city":"Szombathely","zip":"9700","country":"Hungary","geoPoint":{"lat":47.23088,"lon":16.62155}},{"city":"Törökbálint","zip":"2045","country":"Hungary","geoPoint":{"lat":47.42931,"lon":18.91356}},{"city":"Milan","zip":"20141","country":"Italy","geoPoint":{"lat":45.46427,"lon":9.18951}},{"city":"Milan","zip":"20162","country":"Italy","geoPoint":{"lat":42.78235,"lon":12.59836}},{"city":"Orbassano","zip":"10043","country":"Italy","geoPoint":{"lat":45.00547,"lon":7.53813}},{"city":"Roma","zip":"00168","country":"Italy","geoPoint":{"lat":44.99364,"lon":11.10642}},{"city":"Enschede","zip":"7500 KA","country":"Netherlands","geoPoint":{"lat":52.21833,"lon":6.89583}},{"city":"Hoorn","zip":"1624 NP","country":"Netherlands","geoPoint":{"lat":52.6425,"lon":5.05972}},{"city":"Nieuwegein","zip":"3435 CM","country":"Netherlands","geoPoint":{"lat":52.02917,"lon":5.08056}},{"city":"Rotterdam","zip":"3075 EA","country":"Netherlands","geoPoint":{"lat":51.9225,"lon":4.47917}},{"city":"The Hague","zip":"2504 LN","country":"Netherlands","geoPoint":{"lat":52.07667,"lon":4.29861}},{"city":"Poznan","zip":"60-569","country":"Poland","geoPoint":{"lat":52.40692,"lon":16.92993}},{"city":"Warsaw","zip":"02-781","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"city":"Zabrze","zip":"41-843","country":"Poland","geoPoint":{"lat":50.32492,"lon":18.78576}},{"city":"Arkhangelsk","zip":"163045","country":"Russia","geoPoint":{"lat":64.5461,"lon":40.55183}},{"city":"Chelyabinsk","zip":"454 087","country":"Russia","geoPoint":{"lat":55.1611,"lon":61.42877}},{"city":"Kazan'","zip":"420029","country":"Russia","geoPoint":{"lat":55.78874,"lon":49.12214}},{"city":"Kazan'","zip":"420111","country":"Russia","geoPoint":{"lat":55.78874,"lon":49.12214}},{"city":"Krasnodar","zip":"350040","country":"Russia","geoPoint":{"lat":45.04534,"lon":38.98178}},{"city":"Krasnodar","zip":"350086","country":"Russia","geoPoint":{"lat":45.04534,"lon":38.98178}},{"city":"Moscow","zip":"105229","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"city":"Moscow","zip":"115478","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"city":"Saint Petersburg","zip":"197089","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"city":"Saint Petersburg","zip":"197758","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"city":"Seville","state":"Sevilla","zip":"41013","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"city":"Valencia","state":"Valencia","zip":"46009","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}},{"city":"Valencia","state":"Valencia","zip":"46010","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}},{"city":"Barakaldo","state":"Vizcaya","zip":"48903","country":"Spain","geoPoint":{"lat":43.29639,"lon":-2.98813}},{"city":"Changhua","zip":"500","country":"Taiwan","geoPoint":{"lat":24.0692,"lon":120.5512}},{"city":"Taichung","zip":"402","country":"Taiwan","geoPoint":{"lat":24.1469,"lon":120.6839}},{"city":"Taichung","zip":"404","country":"Taiwan","geoPoint":{"lat":24.1469,"lon":120.6839}},{"city":"Taichung","zip":"407","country":"Taiwan","geoPoint":{"lat":24.1469,"lon":120.6839}},{"city":"Taipei","zip":"100","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"city":"Aberdeen","zip":"AB25 2ZN","country":"United Kingdom","geoPoint":{"lat":57.14369,"lon":-2.09814}},{"city":"Chelmsford","zip":"CM1 7ET","country":"United Kingdom","geoPoint":{"lat":51.73575,"lon":0.46958}},{"city":"London","zip":"SE1 9RT","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Bevacizumab 7.5 Milligrams (mg) Plus Chemotherapy","description":"Cycles 1-6 (3-week cycles): Participants received bevacizumab 7.5 mg per kilogram (mg/kg) intravenously (IV) on Day 1; either carboplatin at a dose required to achieve an area under the concentration-time curve (AUC) of 6 mg per milliliter (mg/mL) IV and paclitaxel 200 mg per square meter (mg/m\\^2) IV on Day 1, or carboplatin at AUC 5 mg/mL IV on Day 1 and gemcitabine 1200 mg/m\\^2 IV on Days 1 and 8. The choice of chemotherapy doublet, either carboplatin/paclitaxel or carboplatin/gemcitabine, was left to the discretion of the investigator. The cycle was repeated until disease progression or for a maximum of 6 cycles.\n\nCycle 7 and beyond (3-week cycles): If the first 6 cycles were tolerated with no disease progression, participants then received bevacizumab 7.5 mg/kg IV on Day 1. This cycle was repeated every 3 weeks until disease progression."},{"id":"FG001","title":"Bevacizumab 15 mg Plus Chemotherapy","description":"Cycles 1-6 (3-week cycles): Participants received bevacizumab 15 mg/kg IV on Day 1; either carboplatin at a dose required to achieve an AUC of 6 mg/mL IV and paclitaxel 200 mg/m\\^2 IV on Day 1, or carboplatin at AUC 5 mg/mL IV on Day 1 and gemcitabine 1200 mg/m\\^2 IV on Days 1 and 8. The choice of chemotherapy doublet, either carboplatin/paclitaxel or carboplatin/gemcitabine, was left to the discretion of the investigator. The cycle was repeated until disease progression or for a maximum of 6 cycles.\n\nCycle 7 and beyond (3-week cycles): If the first 6 cycles were tolerated with no disease progression, participants then received bevacizumab 15 mg/kg IV on Day 1. This cycle was repeated every 3 weeks until disease progression."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"154"},{"groupId":"FG001","numSubjects":"149"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","comment":"Clinical cutoff date: July 11, 2011","numSubjects":"0"},{"groupId":"FG001","comment":"Clinical cutoff date: July 11, 2011","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"154"},{"groupId":"FG001","numSubjects":"149"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"99"},{"groupId":"FG001","numSubjects":"114"}]},{"type":"Alive on treatment","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Alive in follow-up","reasons":[{"groupId":"FG000","numSubjects":"46"},{"groupId":"FG001","numSubjects":"27"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"5"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Intent-to-treat (ITT) population. The ITT population included all participants randomized into the study.","groups":[{"id":"BG000","title":"Bevacizumab 7.5 mg Plus Chemotherapy","description":"Cycles 1-6 (3-week cycles): Participants received bevacizumab 7.5 mg/kg IV on Day 1; either carboplatin at a dose required to achieve an AUC of 6 mg/mL IV and paclitaxel 200 mg/m\\^2 IV on Day 1, or carboplatin at AUC 5 mg/mL IV on Day 1 and gemcitabine 1200 mg/m\\^2 IV on Days 1 and 8. The choice of chemotherapy doublet, either carboplatin/paclitaxel or carboplatin/gemcitabine, was left to the discretion of the investigator. The cycle was repeated until disease progression or for a maximum of 6 cycles.\n\nCycle 7 and beyond (3-week cycles): If the first 6 cycles were tolerated with no disease progression, participants then received bevacizumab 7.5 mg/kg IV on Day 1. This cycle was repeated every 3 weeks until disease progression."},{"id":"BG001","title":"Bevacizumab 15 mg Plus Chemotherapy","description":"Cycles 1-6 (3-week cycles): Participants received bevacizumab 15 mg/kg IV on Day 1; either carboplatin at a dose required to achieve an AUC of 6 mg/mL IV and paclitaxel 200 mg/m\\^2 IV on Day 1, or carboplatin at AUC 5 mg/mL IV on Day 1 and gemcitabine 1200 mg/m\\^2 IV on Days 1 and 8. The choice of chemotherapy doublet, either carboplatin/paclitaxel or carboplatin/gemcitabine, was left to the discretion of the investigator. The cycle was repeated until disease progression or for a maximum of 6 cycles.\n\nCycle 7 and beyond (3-week cycles): If the first 6 cycles were tolerated with no disease progression, participants then received bevacizumab 15 mg/kg IV on Day 1. This cycle was repeated every 3 weeks until disease progression."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"154"},{"groupId":"BG001","value":"149"},{"groupId":"BG002","value":"303"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"59.7","spread":"10.13"},{"groupId":"BG001","value":"58.8","spread":"11.20"},{"groupId":"BG002","value":"59.2","spread":"10.66"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"56"},{"groupId":"BG001","value":"55"},{"groupId":"BG002","value":"111"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"98"},{"groupId":"BG001","value":"94"},{"groupId":"BG002","value":"192"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) by Dichotomized Baseline Plasma Marker Level","description":"Overall response was analyzed and correlated within dichotomized (low- and high-level) baseline plasma biomarker (basic fibroblast growth factor \\[bFGF\\], E-selection, intracellular adhesion molecule \\[ICAM\\], placental growth factor \\[PlGF\\], vascular endothelial growth factor A \\[VEGF A\\], vascular endothelial growth factor receptor \\[VEGFR\\]-1, and VEGFR-2) subgroups: low-level equals (=) less than or equal to (≤) median baseline level, high-level=greater than (\\>) median baseline level. Per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.0 CR defined as disappearance of all target lesions, non-target lesions, and normalization of tumor marker level. PR defined as greater than or equal to (≥)30 percent (%) decrease under baseline of the sum of the longest diameter (LD) of all target lesions. No unequivocal progression of non-target disease; no new lesions. Complete and partial responses must have been confirmed no less than 4 weeks after criteria for response were first met","populationDescription":"Biomarker Evaluable Protein Plasma (BEP) Population: Participants in the ITT population who started at least 1 dose of bevacizumab and had a non-missing baseline biomarker level determined for at least 1 biomarker. n (number) equals (=) number of participants assessed for the specified biomarker.","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Baseline, Day 21 of Cycles 2, 4, and 6 (Bv + chemo), Day 21 of Cycles 7, 8, 9, and 10 (Bv), Day 21 of every other cycle (Bv), and at disease progression.","groups":[{"id":"OG000","title":"Bevacizumab 7.5 mg Plus Chemotherapy","description":"Cycles 1-6 (3-week cycles): Participants received bevacizumab 7.5 mg/kg IV on Day 1; either carboplatin at a dose required to achieve an AUC of 6 mg/mL IV and paclitaxel 200 mg/m\\^2 IV on Day 1, or carboplatin at AUC 5 mg/mL IV on Day 1 and gemcitabine 1200 mg/m\\^2 IV on Days 1 and 8. The choice of chemotherapy doublet, either carboplatin/paclitaxel or carboplatin/gemcitabine, was left to the discretion of the investigator. The cycle was repeated until disease progression or for a maximum of 6 cycles.\n\nCycle 7 and beyond (3-week cycles): If the first 6 cycles were tolerated with no disease progression, participants then received bevacizumab 7.5 mg/kg IV on Day 1. This cycle was repeated every 3 weeks until disease progression."},{"id":"OG001","title":"Bevacizumab 15 mg Plus Chemotherapy","description":"Cycles 1-6 (3-week cycles): Participants received bevacizumab 15 mg/kg IV on Day 1; either carboplatin at a dose required to achieve an AUC of 6 mg/mL IV and paclitaxel 200 mg/m\\^2 IV on Day 1, or carboplatin at AUC 5 mg/mL IV on Day 1 and gemcitabine 1200 mg/m\\^2 IV on Days 1 and 8. The choice of chemotherapy doublet, either carboplatin/paclitaxel or carboplatin/gemcitabine, was left to the discretion of the investigator. The cycle was repeated until disease progression or for a maximum of 6 cycles.\n\nCycle 7 and beyond (3-week cycles): If the first 6 cycles were tolerated with no disease progression, participants then received bevacizumab 15 mg/kg IV on Day 1. This cycle was repeated every 3 weeks until disease progression."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"75"}]}],"classes":[{"title":"bFGF low level (n=77,65)","categories":[{"measurements":[{"groupId":"OG000","value":"42.86"},{"groupId":"OG001","value":"47.69"}]}]},{"title":"bFGF high level (n=66,75)","categories":[{"measurements":[{"groupId":"OG000","value":"34.85"},{"groupId":"OG001","value":"49.33"}]}]},{"title":"E-selectin low level (n=73,69)","categories":[{"measurements":[{"groupId":"OG000","value":"36.99"},{"groupId":"OG001","value":"42.03"}]}]},{"title":"E-selectin high level (n=70,71)","categories":[{"measurements":[{"groupId":"OG000","value":"41.43"},{"groupId":"OG001","value":"54.93"}]}]},{"title":"ICAM low level (n=70,72)","categories":[{"measurements":[{"groupId":"OG000","value":"38.57"},{"groupId":"OG001","value":"50.00"}]}]},{"title":"ICAM high level (n=29,32","categories":[{"measurements":[{"groupId":"OG000","value":"39.73"},{"groupId":"OG001","value":"47.06"}]}]},{"title":"PlGF low level (n=82, 64)","categories":[{"measurements":[{"groupId":"OG000","value":"37.80"},{"groupId":"OG001","value":"51.56"}]}]},{"title":"PlGF high level (n=27,29)","categories":[{"measurements":[{"groupId":"OG000","value":"33.33"},{"groupId":"OG001","value":"51.72"}]}]},{"title":"VEGF A low level (n=73,67)","categories":[{"measurements":[{"groupId":"OG000","value":"42.47"},{"groupId":"OG001","value":"44.78"}]}]},{"title":"VEGF A high level (n=67,73)","categories":[{"measurements":[{"groupId":"OG000","value":"35.82"},{"groupId":"OG001","value":"53.42"}]}]},{"title":"VEGFR-1 low level (n=72,70)","categories":[{"measurements":[{"groupId":"OG000","value":"37.50"},{"groupId":"OG001","value":"60.00"}]}]},{"title":"VEGFR-1 high level (n=71,70)","categories":[{"measurements":[{"groupId":"OG000","value":"40.85"},{"groupId":"OG001","value":"37.14"}]}]},{"title":"VEGFR-2 low level (n=74,69)","categories":[{"measurements":[{"groupId":"OG000","value":"32.43"},{"groupId":"OG001","value":"46.38"}]}]},{"title":"VEGFR-2 high level (n=69,71)","categories":[{"measurements":[{"groupId":"OG000","value":"46.38"},{"groupId":"OG001","value":"50.70"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"bFGF (high versus low)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.8127","pValueComment":"Multiple logistic regression model with treatment, biomarker level (dichotomized) and baseline prognostic factors as covariates.","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"1.07","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.63","ciUpperLimit":"1.80"},{"groupIds":["OG000"],"groupDescription":"E-selectin (high versus low)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0285","pValueComment":"Multiple logistic regression model with treatment, biomarker level (dichotomized) and baseline prognostic factors as covariates.","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"1.81","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.06","ciUpperLimit":"3.08"},{"groupIds":["OG000"],"groupDescription":"ICAM (high versus low)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.7478","pValueComment":"Multiple logistic regression model with treatment, biomarker level (dichotomized) and baseline prognostic factors as covariates.","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"1.09","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.64","ciUpperLimit":"1.85"},{"groupIds":["OG000"],"groupDescription":"PlGF (high versus low)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.6761","pValueComment":"Multiple logistic regression model with treatment, biomarker level (dichotomized) and baseline prognostic factors as covariates.","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"1.16","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.58","ciUpperLimit":"2.33"},{"groupIds":["OG000"],"groupDescription":"VEGF A (high versus low)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.4601","pValueComment":"Multiple logistic regression model with treatment, biomarker level (dichotomized) and baseline prognostic factors as covariates.","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"1.22","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.72","ciUpperLimit":"2.09"},{"groupIds":["OG000"],"groupDescription":"VEGFR-1 (high versus low)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.3193","pValueComment":"Multiple logistic regression model with treatment, biomarker level (dichotomized) and baseline prognostic factors as covariates.","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"0.77","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.46","ciUpperLimit":"1.29"},{"groupIds":["OG000"],"groupDescription":"VEGFR-2 (high versus low)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1758","pValueComment":"Multiple logistic regression model with treatment, biomarker level (dichotomized) and baseline prognostic factors as covariates.","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"1.44","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.85","ciUpperLimit":"2.45"}]},{"type":"SECONDARY","title":"Progression-Free Survival - Percentage of Participants With an Event","description":"PFS was defined as the time between randomization and progressive disease (PD) according to RECIST criteria, or death due to any cause. PD was defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started. Disease progression was evaluated according to the RECIST using computed tomography (CT) scans, magnetic resonance imaging (MRI) scans, X-ray, bone scans, or clinical examination. Participants without an event were censored at the date of last follow up for progression. Participants with no post baseline follow-up for progression were censored at the day of randomization.","populationDescription":"ITT population.","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Baseline, Day 1, weekly to disease progression","groups":[{"id":"OG000","title":"Bevacizumab 7.5 mg Plus Chemotherapy","description":"Cycles 1-6 (3-week cycles): Participants received bevacizumab 7.5 mg/kg IV on Day 1; either carboplatin at a dose required to achieve an AUC of 6 mg/mL IV and paclitaxel 200 mg/m\\^2 IV on Day 1, or carboplatin at AUC 5 mg/mL IV on Day 1 and gemcitabine 1200 mg/m\\^2 IV on Days 1 and 8. The choice of chemotherapy doublet, either carboplatin/paclitaxel or carboplatin/gemcitabine, was left to the discretion of the investigator. The cycle was repeated until disease progression or for a maximum of 6 cycles.\n\nCycle 7 and beyond (3-week cycles): If the first 6 cycles were tolerated with no disease progression, participants then received bevacizumab 7.5 mg/kg IV on Day 1. This cycle was repeated every 3 weeks until disease progression."},{"id":"OG001","title":"Bevacizumab 15 mg Plus Chemotherapy","description":"Cycles 1-6 (3-week cycles): Participants received bevacizumab 15 mg/kg IV on Day 1; either carboplatin at a dose required to achieve an AUC of 6 mg/mL IV and paclitaxel 200 mg/m\\^2 IV on Day 1, or carboplatin at AUC 5 mg/mL IV on Day 1 and gemcitabine 1200 mg/m\\^2 IV on Days 1 and 8. The choice of chemotherapy doublet, either carboplatin/paclitaxel or carboplatin/gemcitabine, was left to the discretion of the investigator. The cycle was repeated until disease progression or for a maximum of 6 cycles.\n\nCycle 7 and beyond (3-week cycles): If the first 6 cycles were tolerated with no disease progression, participants then received bevacizumab 15 mg/kg IV on Day 1. This cycle was repeated every 3 weeks until disease progression."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"154"},{"groupId":"OG001","value":"149"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.1"},{"groupId":"OG001","value":"85.9"}]}]}]},{"type":"SECONDARY","title":"Progression-Free Survival - Time to Event","description":"PFS was defined as the time between randomization and disease progression or death due to any cause. Participants without an event were censored at the date of last follow up for progression. Participants with no post baseline follow-up for progression were censored at the day of randomization. Disease progression was evaluated according to the RECIST using CT scans, MRI scans, X-ray, bone scans, or clinical examination. Median PFS was estimated using the Kaplan-Meier method.","populationDescription":"ITT Population.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Baseline, Day 1, weekly to disease progression","groups":[{"id":"OG000","title":"Bevacizumab 7.5 mg Plus Chemotherapy","description":"Cycles 1-6 (3-week cycles): Participants received bevacizumab 7.5 mg/kg IV on Day 1; either carboplatin at a dose required to achieve an AUC of 6 mg/mL IV and paclitaxel 200 mg/m\\^2 IV on Day 1, or carboplatin at AUC 5 mg/mL IV on Day 1 and gemcitabine 1200 mg/m\\^2 IV on Days 1 and 8. The choice of chemotherapy doublet, either carboplatin/paclitaxel or carboplatin/gemcitabine, was left to the discretion of the investigator. The cycle was repeated until disease progression or for a maximum of 6 cycles.\n\nCycle 7 and beyond (3-week cycles): If the first 6 cycles were tolerated with no disease progression, participants then received bevacizumab 7.5 mg/kg IV on Day 1. This cycle was repeated every 3 weeks until disease progression."},{"id":"OG001","title":"Bevacizumab 15 mg Plus Chemotherapy","description":"Cycles 1-6 (3-week cycles): Participants received bevacizumab 15 mg/kg IV on Day 1; either carboplatin at a dose required to achieve an AUC of 6 mg/mL IV and paclitaxel 200 mg/m\\^2 IV on Day 1, or carboplatin at AUC 5 mg/mL IV on Day 1 and gemcitabine 1200 mg/m\\^2 IV on Days 1 and 8. The choice of chemotherapy doublet, either carboplatin/paclitaxel or carboplatin/gemcitabine, was left to the discretion of the investigator. The cycle was repeated until disease progression or for a maximum of 6 cycles.\n\nCycle 7 and beyond (3-week cycles): If the first 6 cycles were tolerated with no disease progression, participants then received bevacizumab 15 mg/kg IV on Day 1. This cycle was repeated every 3 weeks until disease progression."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"154"},{"groupId":"OG001","value":"149"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.8","lowerLimit":"5.9","upperLimit":"7.4"},{"groupId":"OG001","value":"6.7","lowerLimit":"5.9","upperLimit":"7.2"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.9454","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.01","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.78","ciUpperLimit":"1.31"}]},{"type":"SECONDARY","title":"Percentage of Participants With Objective Response","description":"Percentage of participants with CR or PR according to RECIST criteria. Per RECIST v1.0: CR defined as disappearance of all target lesions, non-target lesions, and normalization of tumor marker level. PR was defined as ≥30% decrease under baseline of the sum of the LD of all target lesions. No unequivocal progression of non-target disease. No new lesions. Complete and partial responses were confirmed no less than 4 weeks after the criteria for response were first met.","populationDescription":"ITT Population. Data for 12 participants (3 at 7.5 mg and 9 at 15 mg) were excluded for reasons including but not limited to: no study treatment (ST), no postbaseline tumor assessment (TA), non-protocol defined antineoplastic therapy before first TA, first TA \\>70 days after last dose of last ST, last TA less than (\\<) 42 days from start of therapy.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Baseline, Day 21 of Cycles 2, 4, and 6, Day 21 of Cycles 7, 8, 9, and 10, Day 21 of every other cycle, and at disease progression","groups":[{"id":"OG000","title":"Bevacizumab 7.5 mg Plus Chemotherapy","description":"Cycles 1-6 (3-week cycles): Participants received bevacizumab 7.5 mg/kg IV on Day 1; either carboplatin at a dose required to achieve an AUC of 6 mg/mL IV and paclitaxel 200 mg/m\\^2 IV on Day 1, or carboplatin at AUC 5 mg/mL IV on Day 1 and gemcitabine 1200 mg/m\\^2 IV on Days 1 and 8. The choice of chemotherapy doublet, either carboplatin/paclitaxel or carboplatin/gemcitabine, was left to the discretion of the investigator. The cycle was repeated until disease progression or for a maximum of 6 cycles.\n\nCycle 7 and beyond (3-week cycles): If the first 6 cycles were tolerated with no disease progression, participants then received bevacizumab 7.5 mg/kg IV on Day 1. This cycle was repeated every 3 weeks until disease progression."},{"id":"OG001","title":"Bevacizumab 15 mg Plus Chemotherapy","description":"Cycles 1-6 (3-week cycles): Participants received bevacizumab 15 mg/kg IV on Day 1; either carboplatin at a dose required to achieve an AUC of 6 mg/mL IV and paclitaxel 200 mg/m\\^2 IV on Day 1, or carboplatin at AUC 5 mg/mL IV on Day 1 and gemcitabine 1200 mg/m\\^2 IV on Days 1 and 8. The choice of chemotherapy doublet, either carboplatin/paclitaxel or carboplatin/gemcitabine, was left to the discretion of the investigator. The cycle was repeated until disease progression or for a maximum of 6 cycles.\n\nCycle 7 and beyond (3-week cycles): If the first 6 cycles were tolerated with no disease progression, participants then received bevacizumab 15 mg/kg IV on Day 1. This cycle was repeated every 3 weeks until disease progression."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"154"},{"groupId":"OG001","value":"149"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.1","lowerLimit":"29.4","upperLimit":"45.3"},{"groupId":"OG001","value":"46.4","lowerLimit":"38.0","upperLimit":"55.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1737","statisticalMethod":"Cochran-Mantel-Haenszel","paramType":"Difference in Responses Rates","paramValue":"9.34","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.4","ciUpperLimit":"21.0","estimateComment":"Approximate 95% Confidence Interval (CI) for difference of two rates using Hauck-Anderson method."}]},{"type":"SECONDARY","title":"Percentage of Participants With Measurable Disease at Baseline Who Achieved CR, PR, or Stable Disease (SD) for at Least 6 Weeks","description":"Percentage of participants with measurable disease at baseline who on assessment achieved CR, PR, or SD according to RECIST. Per RECIST v1.0: CR defined as disappearance of all target lesions, non-target lesions, and normalization of tumor marker level. PR was defined as ≥30% decrease under baseline of the sum of the LD of all target lesions. No unequivocal progression of non-target disease. No new lesions. SD defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum LD since start of treatment. Complete and partial responses must have been confirmed no less than 4 weeks after the criteria for response were first met. For participants with SD, follow-up assessments must have met the SD criteria at least once after study entry at a minimum interval of 6 weeks.","populationDescription":"ITT Population","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Baseline, Day 21 of Cycles 2, 4, and 6, Day 21 of Cycles 7, 8, 9, and 10, Day 21 of every other cycle, and at disease progression","groups":[{"id":"OG000","title":"Bevacizumab 7.5 mg Plus Chemotherapy","description":"Cycles 1-6 (3-week cycles): Participants received bevacizumab 7.5 mg/kg IV on Day 1; either carboplatin at a dose required to achieve an AUC of 6 mg/mL IV and paclitaxel 200 mg/m\\^2 IV on Day 1, or carboplatin at AUC 5 mg/mL IV on Day 1 and gemcitabine 1200 mg/m\\^2 IV on Days 1 and 8. The choice of chemotherapy doublet, either carboplatin/paclitaxel or carboplatin/gemcitabine, was left to the discretion of the investigator. The cycle was repeated until disease progression or for a maximum of 6 cycles.\n\nCycle 7 and beyond (3-week cycles): If the first 6 cycles were tolerated with no disease progression, participants then received bevacizumab 7.5 mg/kg IV on Day 1. This cycle was repeated every 3 weeks until disease progression."},{"id":"OG001","title":"Bevacizumab 15 mg Plus Chemotherapy","description":"Cycles 1-6 (3-week cycles): Participants received bevacizumab 15 mg/kg IV on Day 1; either carboplatin at a dose required to achieve an AUC of 6 mg/mL IV and paclitaxel 200 mg/m\\^2 IV on Day 1, or carboplatin at AUC 5 mg/mL IV on Day 1 and gemcitabine 1200 mg/m\\^2 IV on Days 1 and 8. The choice of chemotherapy doublet, either carboplatin/paclitaxel or carboplatin/gemcitabine, was left to the discretion of the investigator. The cycle was repeated until disease progression or for a maximum of 6 cycles.\n\nCycle 7 and beyond (3-week cycles): If the first 6 cycles were tolerated with no disease progression, participants then received bevacizumab 15 mg/kg IV on Day 1. This cycle was repeated every 3 weeks until disease progression."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"151"},{"groupId":"OG001","value":"140"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76.8","lowerLimit":"69.3","upperLimit":"83.3"},{"groupId":"OG001","value":"78.6","lowerLimit":"70.8","upperLimit":"85.1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.6148","statisticalMethod":"Cochran-Mantel-Haenszel","paramType":"Mean Difference (Final Values)","paramValue":"1.75","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-8.2","ciUpperLimit":"11.7","estimateComment":"Approximate 95% CI for difference of two rates using Hauck-Anderson method"}]},{"type":"SECONDARY","title":"Duration of Response - Percentage of Participants With an Event","description":"Duration of response is defined as time in months from the first documentation of objective tumor response (CR or PR) to objective tumor progression or death due to any cause. Participants without an event (documented progression or death) were censored at the date of last follow-up for progression. Duration of response was only calculated for participants who had a confirmed objective tumor response (CR or PR).","populationDescription":"ITT population; only participants with an objective tumor response (CR or PR) were included in the analysis.","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Baseline, Day 21 of Cycles 2, 4, and 6, Day 21 of Cycles 7, 8, 9, and 10, Day 21 of every other cycle, and at disease progression","groups":[{"id":"OG000","title":"Bevacizumab 7.5 mg Plus Chemotherapy","description":"Cycles 1-6 (3-week cycles): Participants received bevacizumab 7.5 mg/kg IV on Day 1; either carboplatin at a dose required to achieve an AUC of 6 mg/mL IV and paclitaxel 200 mg/m\\^2 IV on Day 1, or carboplatin at AUC 5 mg/mL IV on Day 1 and gemcitabine 1200 mg/m\\^2 IV on Days 1 and 8. The choice of chemotherapy doublet, either carboplatin/paclitaxel or carboplatin/gemcitabine, was left to the discretion of the investigator. The cycle was repeated until disease progression or for a maximum of 6 cycles.\n\nCycle 7 and beyond (3-week cycles): If the first 6 cycles were tolerated with no disease progression, participants then received bevacizumab 7.5 mg/kg IV on Day 1. This cycle was repeated every 3 weeks until disease progression."},{"id":"OG001","title":"Bevacizumab 15 mg Plus Chemotherapy","description":"Cycles 1-6 (3-week cycles): Participants received bevacizumab 15 mg/kg IV on Day 1; either carboplatin at a dose required to achieve an AUC of 6 mg/mL IV and paclitaxel 200 mg/m\\^2 IV on Day 1, or carboplatin at AUC 5 mg/mL IV on Day 1 and gemcitabine 1200 mg/m\\^2 IV on Days 1 and 8. The choice of chemotherapy doublet, either carboplatin/paclitaxel or carboplatin/gemcitabine, was left to the discretion of the investigator. The cycle was repeated until disease progression or for a maximum of 6 cycles.\n\nCycle 7 and beyond (3-week cycles): If the first 6 cycles were tolerated with no disease progression, participants then received bevacizumab 15 mg/kg IV on Day 1. This cycle was repeated every 3 weeks until disease progression."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"65"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.4"},{"groupId":"OG001","value":"78.5"}]}]}]},{"type":"SECONDARY","title":"Duration of Response - Time to Event","description":"The median time, in months, from the first documentation of objective tumor response (CR or PR) to objective tumor progression or death due to any cause. Participants without an event (documented progression or death) were censored at the date of last follow-up for progression. Duration of response was only calculated for participants who had a confirmed objective tumor response (CR or PR). Median Duration of Response was estimated using the Kaplan-Meier method.","populationDescription":"ITT population: only participants with an objective tumor response (CR or PR) were included in the analysis.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Baseline, Day 21 of Cycles 2, 4, and 6 (Bv + chemo), Day 21 of Cycles 7, 8, 9, and 10 (Bv), Day 21 of every other cycle (Bv), and at disease progression.","groups":[{"id":"OG000","title":"Bevacizumab 7.5 mg Plus Chemotherapy","description":"Cycles 1-6 (3-week cycles): Participants received bevacizumab 7.5 mg/kg IV on Day 1; either carboplatin at a dose required to achieve an AUC of 6 mg/mL IV and paclitaxel 200 mg/m\\^2 IV on Day 1, or carboplatin at AUC 5 mg/mL IV on Day 1 and gemcitabine 1200 mg/m\\^2 IV on Days 1 and 8. The choice of chemotherapy doublet, either carboplatin/paclitaxel or carboplatin/gemcitabine, was left to the discretion of the investigator. The cycle was repeated until disease progression or for a maximum of 6 cycles.\n\nCycle 7 and beyond (3-week cycles): If the first 6 cycles were tolerated with no disease progression, participants then received bevacizumab 7.5 mg/kg IV on Day 1. This cycle was repeated every 3 weeks until disease progression."},{"id":"OG001","title":"Bevacizumab 15 mg Plus Chemotherapy","description":"Cycles 1-6 (3-week cycles): Participants received bevacizumab 15 mg/kg IV on Day 1; either carboplatin at a dose required to achieve an AUC of 6 mg/mL IV and paclitaxel 200 mg/m\\^2 IV on Day 1, or carboplatin at AUC 5 mg/mL IV on Day 1 and gemcitabine 1200 mg/m\\^2 IV on Days 1 and 8. The choice of chemotherapy doublet, either carboplatin/paclitaxel or carboplatin/gemcitabine, was left to the discretion of the investigator. The cycle was repeated until disease progression or for a maximum of 6 cycles.\n\nCycle 7 and beyond (3-week cycles): If the first 6 cycles were tolerated with no disease progression, participants then received bevacizumab 15 mg/kg IV on Day 1. This cycle was repeated every 3 weeks until disease progression."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"65"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.8","lowerLimit":"5.2","upperLimit":"7.0"},{"groupId":"OG001","value":"5.6","lowerLimit":"4.6","upperLimit":"7.1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.7587","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.07","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.68","ciUpperLimit":"1.69"}]},{"type":"SECONDARY","title":"Overall Survival - Percentage of Participants With an Event","description":"Overall survival was defined as the time between randomization and death due to any cause. Participants without an event were censored at the last time they were known to be alive. Overall Survival was estimated using the Kaplan-Meier method.","populationDescription":"ITT population.","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Baseline, weekly to 28 days after last dose of study treatment, every 8 weeks thereafter to death due to any cause","groups":[{"id":"OG000","title":"Bevacizumab 7.5 mg Plus Chemotherapy","description":"Cycles 1-6 (3-week cycles): Participants received bevacizumab 7.5 mg/kg IV on Day 1; either carboplatin at a dose required to achieve an AUC of 6 mg/mL IV and paclitaxel 200 mg/m\\^2 IV on Day 1, or carboplatin at AUC 5 mg/mL IV on Day 1 and gemcitabine 1200 mg/m\\^2 IV on Days 1 and 8. The choice of chemotherapy doublet, either carboplatin/paclitaxel or carboplatin/gemcitabine, was left to the discretion of the investigator. The cycle was repeated until disease progression or for a maximum of 6 cycles.\n\nCycle 7 and beyond (3-week cycles): If the first 6 cycles were tolerated with no disease progression, participants then received bevacizumab 7.5 mg/kg IV on Day 1. This cycle was repeated every 3 weeks until disease progression."},{"id":"OG001","title":"Bevacizumab 15 mg Plus Chemotherapy","description":"Cycles 1-6 (3-week cycles): Participants received bevacizumab 15 mg/kg IV on Day 1; either carboplatin at a dose required to achieve an AUC of 6 mg/mL IV and paclitaxel 200 mg/m\\^2 IV on Day 1, or carboplatin at AUC 5 mg/mL IV on Day 1 and gemcitabine 1200 mg/m\\^2 IV on Days 1 and 8. The choice of chemotherapy doublet, either carboplatin/paclitaxel or carboplatin/gemcitabine, was left to the discretion of the investigator. The cycle was repeated until disease progression or for a maximum of 6 cycles.\n\nCycle 7 and beyond (3-week cycles): If the first 6 cycles were tolerated with no disease progression, participants then received bevacizumab 15 mg/kg IV on Day 1. This cycle was repeated every 3 weeks until disease progression."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"154"},{"groupId":"OG001","value":"149"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.3"},{"groupId":"OG001","value":"76.5"}]}]}]},{"type":"SECONDARY","title":"Overall Survival - Time to Event","description":"Overall survival was defined as the time between randomization and death due to any cause. Participants without an event were censored at the last time they were known to be alive. Overall Survival was estimated using the Kaplan-Meier method.","populationDescription":"ITT Population.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Baseline, weekly to death due to any cause, or to end of study","groups":[{"id":"OG000","title":"Bevacizumab 7.5 mg Plus Chemotherapy","description":"Cycles 1-6 (3-week cycles): Participants received bevacizumab 7.5 mg/kg IV on Day 1; either carboplatin at a dose required to achieve an AUC of 6 mg/mL IV and paclitaxel 200 mg/m\\^2 IV on Day 1, or carboplatin at AUC 5 mg/mL IV on Day 1 and gemcitabine 1200 mg/m\\^2 IV on Days 1 and 8. The choice of chemotherapy doublet, either carboplatin/paclitaxel or carboplatin/gemcitabine, was left to the discretion of the investigator. The cycle was repeated until disease progression or for a maximum of 6 cycles.\n\nCycle 7 and beyond (3-week cycles): If the first 6 cycles were tolerated with no disease progression, participants then received bevacizumab 7.5 mg/kg IV on Day 1. This cycle was repeated every 3 weeks until disease progression."},{"id":"OG001","title":"Bevacizumab 15 mg Plus Chemotherapy","description":"Cycles 1-6 (3-week cycles): Participants received bevacizumab 15 mg/kg IV on Day 1; either carboplatin at a dose required to achieve an AUC of 6 mg/mL IV and paclitaxel 200 mg/m\\^2 IV on Day 1, or carboplatin at AUC 5 mg/mL IV on Day 1 and gemcitabine 1200 mg/m\\^2 IV on Days 1 and 8. The choice of chemotherapy doublet, either carboplatin/paclitaxel or carboplatin/gemcitabine, was left to the discretion of the investigator. The cycle was repeated until disease progression or for a maximum of 6 cycles.\n\nCycle 7 and beyond (3-week cycles): If the first 6 cycles were tolerated with no disease progression, participants then received bevacizumab 15 mg/kg IV on Day 1. This cycle was repeated every 3 weeks until disease progression."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"154"},{"groupId":"OG001","value":"149"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.4","lowerLimit":"10.5","upperLimit":"18.1"},{"groupId":"OG001","value":"13.7","lowerLimit":"11.4","upperLimit":"17.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.3120","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.16","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.87","ciUpperLimit":"1.53"}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Adverse events were assessed from first study treatment until 28 days after last study treatment (LST). In addition, surgical procedures, major injuries and adverse events of special interest for bevacizumab were assessed to at least 6 months after LST.","eventGroups":[{"id":"EG000","title":"Bevacizumab 7.5 mg Plus Chemotherapy","description":"Cycles 1-6 (3-week cycles): Participants received bevacizumab 7.5 mg/kg IV on Day 1; either carboplatin at a dose required to achieve an AUC of 6 mg/mL IV and paclitaxel 200 mg/m\\^2 IV on Day 1, or carboplatin at AUC 5 mg/mL IV on Day 1 and gemcitabine 1200 mg/m\\^2 IV on Days 1 and 8. The choice of chemotherapy doublet, either carboplatin/paclitaxel or carboplatin/gemcitabine, was left to the discretion of the investigator. The cycle was repeated until disease progression or for a maximum of 6 cycles.\n\nCycle 7 and beyond (3-week cycles): If the first 6 cycles were tolerated with no disease progression, participants then received bevacizumab 7.5 mg/kg IV on Day 1. This cycle was repeated every 3 weeks until disease progression.","seriousNumAffected":53,"seriousNumAtRisk":151,"otherNumAffected":137,"otherNumAtRisk":151},{"id":"EG001","title":"Bevacizumab 15 mg Plus Chemotherapy","description":"Cycles 1-6 (3-week cycles): Participants received bevacizumab 15 mg/kg IV on Day 1; either carboplatin at a dose required to achieve an AUC of 6 mg/mL IV and paclitaxel 200 mg/m\\^2 IV on Day 1, or carboplatin at AUC 5 mg/mL IV on Day 1 and gemcitabine 1200 mg/m\\^2 IV on Days 1 and 8. The choice of chemotherapy doublet, either carboplatin/paclitaxel or carboplatin/gemcitabine, was left to the discretion of the investigator. The cycle was repeated until disease progression or for a maximum of 6 cycles.\n\nCycle 7 and beyond (3-week cycles): If the first 6 cycles were tolerated with no disease progression, participants then received bevacizumab 15 mg/kg IV on Day 1. This cycle was repeated every 3 weeks until disease progression.","seriousNumAffected":57,"seriousNumAtRisk":143,"otherNumAffected":132,"otherNumAtRisk":143}],"seriousEvents":[{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":151},{"groupId":"EG001","numAffected":13,"numAtRisk":143}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":151},{"groupId":"EG001","numAffected":7,"numAtRisk":143}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":151},{"groupId":"EG001","numAffected":8,"numAtRisk":143}]},{"term":"Granulocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":143}]},{"term":"Febrile Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":143}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":143}]},{"term":"Bone Marrow Failure","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":143}]},{"term":"Pancytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":143}]},{"term":"Pulmonary Embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":6,"numAtRisk":143}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":151},{"groupId":"EG001","numAffected":3,"numAtRisk":143}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":143}]},{"term":"Chronic Obstructive Pulmonary Disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":143}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":2,"numAtRisk":143}]},{"term":"Bronchitis Chronic","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":143}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":143}]},{"term":"Pleural Effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":143}]},{"term":"Pulmonary Artery Thrombosis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":143}]},{"term":"Pulmonary Haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":143}]},{"term":"Respiratory Failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":143}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":151},{"groupId":"EG001","numAffected":7,"numAtRisk":143}]},{"term":"Pyothorax","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":143}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":2,"numAtRisk":143}]},{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":143}]},{"term":"Bronchopneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":143}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":143}]},{"term":"Localised Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":143}]},{"term":"Lung Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":143}]},{"term":"Neutropenic Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":143}]},{"term":"Pneumonia Legionella","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":143}]},{"term":"Pseudomonal Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":143}]},{"term":"Pulmonary Tuberculosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":143}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":5,"numAtRisk":143}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":143}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":143}]},{"term":"Chest Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":143}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":143}]},{"term":"Cerebral Infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":143}]},{"term":"Cerebrovascular Accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":143}]},{"term":"Neuropathy Peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":143}]},{"term":"Embolic Stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":143}]},{"term":"Ischaemic Stoke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":143}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":143}]},{"term":"Cardiac Failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":2,"numAtRisk":143}]},{"term":"Myocardial Infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":143}]},{"term":"Angina Pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":143}]},{"term":"Left Ventricular Failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":143}]},{"term":"Palapitations","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":143}]},{"term":"Tachycardia Paroxysmal","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":143}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":143}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":143}]},{"term":"Gastric Ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":143}]},{"term":"Intestinal Perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":143}]},{"term":"Melaena","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":143}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":143}]},{"term":"Rectal Haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":143}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":143}]},{"term":"Deep Vein Thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":143}]},{"term":"Hypertensive Crisis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":143}]},{"term":"Arterial Thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":143}]},{"term":"Femur Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":143}]},{"term":"Intestinal Anastomosis Complication","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":143}]},{"term":"Rib Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":143}]},{"term":"Wound Dehiscence","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":143}]},{"term":"Fluid Retension","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":143}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":143}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":143}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":143}]},{"term":"Breast Cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":143}]},{"term":"Cancer Pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":143}]},{"term":"Neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":143}]},{"term":"Renal Failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":143}]},{"term":"Urinary Tract Obstruction","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":143}]},{"term":"Hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":143}]},{"term":"Renal Scan Abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":143}]},{"term":"Musculoskeletal Pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":143}]}],"otherEvents":[{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":72,"numAtRisk":151},{"groupId":"EG001","numAffected":57,"numAtRisk":143}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":62,"numAtRisk":151},{"groupId":"EG001","numAffected":41,"numAtRisk":143}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":54,"numAtRisk":151},{"groupId":"EG001","numAffected":39,"numAtRisk":143}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":28,"numAtRisk":151},{"groupId":"EG001","numAffected":16,"numAtRisk":143}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":52,"numAtRisk":151},{"groupId":"EG001","numAffected":38,"numAtRisk":143}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":27,"numAtRisk":151},{"groupId":"EG001","numAffected":20,"numAtRisk":143}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":151},{"groupId":"EG001","numAffected":22,"numAtRisk":143}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":151},{"groupId":"EG001","numAffected":16,"numAtRisk":143}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":151},{"groupId":"EG001","numAffected":9,"numAtRisk":143}]},{"term":"Mouth ulceration","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":151},{"groupId":"EG001","numAffected":5,"numAtRisk":143}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":151},{"groupId":"EG001","numAffected":5,"numAtRisk":143}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":33,"numAtRisk":151},{"groupId":"EG001","numAffected":37,"numAtRisk":143}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":25,"numAtRisk":151},{"groupId":"EG001","numAffected":18,"numAtRisk":143}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":151},{"groupId":"EG001","numAffected":22,"numAtRisk":143}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":151},{"groupId":"EG001","numAffected":12,"numAtRisk":143}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":151},{"groupId":"EG001","numAffected":12,"numAtRisk":143}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":151},{"groupId":"EG001","numAffected":8,"numAtRisk":143}]},{"term":"Dysphonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":151},{"groupId":"EG001","numAffected":4,"numAtRisk":143}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":47,"numAtRisk":151},{"groupId":"EG001","numAffected":41,"numAtRisk":143}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":151},{"groupId":"EG001","numAffected":9,"numAtRisk":143}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":151},{"groupId":"EG001","numAffected":7,"numAtRisk":143}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":151},{"groupId":"EG001","numAffected":10,"numAtRisk":143}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":151},{"groupId":"EG001","numAffected":9,"numAtRisk":143}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":151},{"groupId":"EG001","numAffected":16,"numAtRisk":143}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":151},{"groupId":"EG001","numAffected":10,"numAtRisk":143}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":151},{"groupId":"EG001","numAffected":12,"numAtRisk":143}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":151},{"groupId":"EG001","numAffected":8,"numAtRisk":143}]},{"term":"Polyneuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":151},{"groupId":"EG001","numAffected":8,"numAtRisk":143}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":35,"numAtRisk":151},{"groupId":"EG001","numAffected":30,"numAtRisk":143}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":151},{"groupId":"EG001","numAffected":11,"numAtRisk":143}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":151},{"groupId":"EG001","numAffected":6,"numAtRisk":143}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":151},{"groupId":"EG001","numAffected":15,"numAtRisk":143}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":151},{"groupId":"EG001","numAffected":13,"numAtRisk":143}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":151},{"groupId":"EG001","numAffected":6,"numAtRisk":143}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":151},{"groupId":"EG001","numAffected":7,"numAtRisk":143}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":27,"numAtRisk":151},{"groupId":"EG001","numAffected":30,"numAtRisk":143}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":151},{"groupId":"EG001","numAffected":26,"numAtRisk":143}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":151},{"groupId":"EG001","numAffected":13,"numAtRisk":143}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":151},{"groupId":"EG001","numAffected":4,"numAtRisk":143}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":151},{"groupId":"EG001","numAffected":13,"numAtRisk":143}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":151},{"groupId":"EG001","numAffected":8,"numAtRisk":143}]},{"term":"Proteinuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":151},{"groupId":"EG001","numAffected":17,"numAtRisk":143}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":151},{"groupId":"EG001","numAffected":9,"numAtRisk":143}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights."},"pointOfContact":{"title":"Medical Communications","organization":"Hoffmann-LaRoche","email":"genentech@druginfo.com","phone":"800-821-8590"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","removedCountries":["China","Singapore"]},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000068258","term":"Bevacizumab"}],"ancestors":[{"id":"D061067","term":"Antibodies, Monoclonal, Humanized"},{"id":"D000911","term":"Antibodies, Monoclonal"},{"id":"D000906","term":"Antibodies"},{"id":"D007136","term":"Immunoglobulins"},{"id":"D007162","term":"Immunoproteins"},{"id":"D001798","term":"Blood Proteins"},{"id":"D011506","term":"Proteins"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D012712","term":"Serum Globulins"},{"id":"D005916","term":"Globulins"}]}},"hasResults":true}